公司资料
BioMarin Pharmaceutical 股价、新闻与催化剂
- 股票代码:
- BMRN
- 交易所:
- NASDAQ
- 行业:
- Gene Therapy
- 所在地:
- San Rafael, California
股票表现
65.08 USD (+0.54%)
收盘价
最后更新: 2026年9月17日
10.3B USD
市值
股价为何变动
截至 2026年9月17日，BMRN 上涨 0.54%，收于 $65.08。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
BioMarin is a rare-disease biotechnology company with a portfolio built around enzyme therapies, rare disease commercialization, and pipeline expansion. It remains one of the clearest pure-play rare-disease names in public biotech.
所在地与行业分类
Headquartered in San Rafael, California and listed on NASDAQ, BioMarin is a U.S.-based rare-disease biotech with global commercial reach. It sits in specialty biotechnology rather than broad pharma.
商业模式特征
The company generates value through orphan-drug commercialization, label expansion, and a pipeline aimed at additional rare conditions. Investors focus on product adoption, revenue growth, and the durability of the rare-disease franchise.
生物医药行业定位
BioMarin occupies a premium niche within biotech because rare disease can support pricing power and durable commercial growth. It is less binary than early-stage oncology names, but data and regulatory milestones still matter.
未来催化剂
- BioMarin’s catalysts are Voxzogo commercial growth, Roctavian uptake, and any enzyme-therapy or gene-therapy update that helps the portfolio. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。